PROC

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") that it has determined to delist the Company's ordinary shares on Nasdaq. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2) for failing to file periodic and interim financial reports. As a result of the forgoing, the Company's ordinary shares are expected to commence trading on the Expert Market operated by the OTC

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") of an additional filing delinquency relating to the Company's interim financial statements for the period ended June 30, 2024. The interim financial statements were required to be filed with Nasdaq by December 31, 2024, but were not for the reasons previously disclosed in connection with the delay in the filing of the Company's Form 20-F for the fiscal yea

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

MIAMI and BARRANQUILLA, Colombia , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced the successful execution of key strategic transactions and governance updates aimed at strengthening its financial position and supporting long-term growth objectives. On November 29, 2024, the Company entered into a Secured Convertible Note Subscription Agreement with Hoche Partners Pharma Holdings S.A. ("Hoche"), pursuant to which the Company may issue up to $40 million in Convertible Notes. Under the agreement, Procaps issued an initial $20 million Convertible Not

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), announced today that, on November 13, 2024, the Company received formal notice from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's failure to timely file the Form 20-F for the fiscal year ended December 31, 2023 (the "Form 20-F") with the U.S. Securities and Exchange Commission (the "SEC"), the Company no longer satisfied Nasdaq Listing Rule 5250(c)(1) (the "Filing Rule") and its securities are therefore subject to suspension and delisting unless the Company timely requests a hearing

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

6-K - Procaps Group, S.A. (0001863362) (Filer)

MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, providing critical updates on the Company's ongoing independent investigation, financial restatement, governance enhancements, and commitment to long-term stability. "Dear Shareholders, As we navigate recent challenges at Procaps, I want to personally reaffirm our dedication to transparency, compliance, and sustainable management. We are committed to addressing the findings from our ongoing investigati

6-K - Procaps Group, S.A. (0001863362) (Filer)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

6-K - Procaps Group, S.A. (0001863362) (Filer)

MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, with updates on the Company's restructuring and strategic plan projects. "Dear Shareholders, We are pleased to update you on several significant developments as we continue to move forward with our strategic plan and financial restructuring efforts. Forbearance Agreements We have successfully signed consolidated forbearance agreements covering approximately an aggregate of $209 million in debt. These ag